p. 203−209
2008-6687
Vol.6/No.4
p. 211−218
2008-6687
Vol.6/No.4
p. 219−228
2008-6687
Vol.6/No.4
T, 2677G>T and 3435C>T in MDR1.Results: The distribution of the three SNPs in responders and poor responders did not show any particular trend (P>0.05). The T allele was slightly higher in responders, but not significantly regardless of the type of SNP (40.3% vs. 33.8% for 1236C>T; 25% vs. 14.7% for 2677G>T and 33.3% vs. 22% for 3435C>T). The dominant model showed a similar trend (P>0.05). Diplotypes composed by the T allele in different exons were frequent in responders. Haplotype analysis showed that 1236C-2677G-3435C was slightly higher in poor responders (60.02%) compared to responders (50.42%). However, 1236T-2677T-3435T was frequent in responders (16.98%) compared to poor responders (13.1%). Overall, none of the haplotypes were associated with IM response in our cohort (global haplotype association test, P=0.39).Conclusion: The identification of 1236C>T, 2677G>T and 3435C>T polymorphisms may not be advantageous to predict imatinib response for our chronic myeloid leukemia patients.]]>
p. 229−235
2008-6687
Vol.6/No.4
p. 237−241
2008-6687
Vol.6/No.4
p. 243−251
2008-6687
Vol.6/No.4
p. 253−265
2008-6687
Vol.6/No.4
p. 267−273
2008-6687
Vol.6/No.4
p. 274−274
2008-6687
Vol.6/No.4